Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2010

View Archived Issues

Bromotetrandrine well tolerated and slowly cleared in healthy volunteers

Genetic association between GCH1 variants and a delay in the onset of cancer pain identified

Anacor discloses new PDE4 inhibitor with anti-inflammatory potential

ROCK-2 inhibitors identified by sanofi-aventis

New drug delivery agents described by University of Missouri-Kansas City

Roche presents full-year results of 2009

Bayer Schering discloses novel mineralocorticoid receptor antagonists

EnVivo claims novel phosphodiesterase 10 inhibitors

Korean researchers discover novel antimitotic agents

Antibody-conjugated magnetic-vortex microdiscs induce cancer cell death in vitro

Candidate plasma protein biomarkers for depression and schizophrenia identified

Roche reports on global phase III Avastin trial in stomach cancer

Extending preventive tuberculosis treatment may reduce illness in patients with HIV

Galapagos completes phase I trial of GLPG-0259 for RA

Catalyst and NIDA to initiate phase IIb trial of CPP-109 for cocaine addiction

FDA does not approve Forest Laboratories' sNDA for Bystolic

Merrimack begins phase I/II trial of MM-121/Tarceva in NSCLC

EMA recommends orphan drug status for Aprea's APR-246 for AML

MEND receives Bill and Melinda Gates Foundation grant to further develop malaria vaccine

Aradigm begins dosing in phase IIb trial of ARD-3100 in BE

Galapagos identifies third candidate drug in arthritis alliance with GSK

Transcept presents update on FDA approval of Intermezzo for insomnia

Catalyst presents update on development plans for CPP-115

European CHMP issues two positive opinions for GSK's Tyverb and Votrient in cancer

Cephalon to acquire Ception following results from phase II Cinquil trial in asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...